|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Prolactin-secreting adenomas (prolactinomas) are the most prevalent form of pituitary tumors in humans, and increased tumor growth under estrogenic influence in female patients is often of clinical concern.
|
11587556 |
2001 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Prolactin-secreting adenomas (prolactinomas) are the most prevalent form of pituitary tumors in humans.
|
16809921 |
2006 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
PRL receptor (PRLR) gene expression was determined by microarrays on aldosterone-producing adenomas and normal adrenals and validated by real-time PCR.
|
26176803 |
2015 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Prolactin-secreting adenomas, or prolactinomas, cause hypogonadism, osteoporosis, and infertility.
|
29726995 |
2018 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Prolactin-secreting adenomas (prolactinomas) are the most common secreting adenomas of the pituitary.
|
30404098 |
2019 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
A 59-year-old man with a giant adenoma in his pituitary had elevated serum prolactin (PRL) and insulin-like growth factor (IGF)-I levels, despite normal levels of basal GH.
|
12008749 |
2002 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A comparative RT-PCR approach revealed signals for both V3 receptor and CHR receptor mRNAs in 17 of 18 ACTH-secreting pituitary adenomas, and 6 of 6 normal pituitaries; in six growth hormone- or prolactin-secreting adenomas, a very faint V3 receptor signal was observed in three cases, and CRH receptor signal was undetected in all.
|
8636444 |
1996 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A functional pituitary adenoma can produce multiple anterior-pituitary hormones, such as growth hormone (GH) -producing adenomas (GHoma) with prolactin or thyrotropin stimulating hormone production in the same lineage.
|
28865461 |
2017 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A significantly higher content of CRABP1 mRNA was observed in NFPA compared to functioning adenomas, and PRL-secreting adenomas showed a lower expression of this gene compared to normal pituitary.
|
21270509 |
2011 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Adrenocorticotrophic hormone-secreting and prolactin-secreting adenomas did not express GHRH-R message.
|
9176381 |
1997 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
AIP mutation-positive patients have a characteristic clinical phenotype with usually young- or childhood-onset growth hormone (GH) and/or prolactin (PRL)-secreting adenomas and can be seen in cases with no apparent family history as well.
|
23652674 |
2013 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
AIP mutations cause a low penetrance autosomal dominant disease with often a distinct phenotype characterized by young-onset, aggressive, large GH, mixed GH and PRL or PRL-secreting adenomas.
|
23310926 |
2012 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Although there were no GH, PRL or TSH-beta transcripts in Pit-1 mRNA-negative ACTH cell and non-functioning adenomas, PRL mRNA was detected in all Pit-1 mRNA-positive ACTH cell adenomas and GH, PRL and/or TSH-beta mRNA were found in four of seven Pit-1 mRNA-positive non-functioning adenomas.
|
8949563 |
1996 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
At last assessment (median follow-up 3 years) and compared with values 6-12 months after stopping DA, Prolactin (PRL) increased in 15%, decreased but not normalized in 33% and was normal in 52%; PRL levels or visible adenoma on imaging before DA withdrawal, treatment duration and presence of macro-/microadenoma at diagnosis were not predictors of normoprolactinaemia at last review, whereas PRL values 6-12 months after stopping DA were.
|
29894000 |
2018 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Bcl-2-associated athanogene (BAG1), an anti-apoptotic protein found at high levels in a number of human cancers, was significantly over-expressed in growth hormone-secreting and prolactin-secreting adenomas and NFPAs.
|
15994756 |
2005 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Because human epidermal growth factor receptor 2 (HER2)/ErbB2 is overexpressed in prolactinomas and ErbB receptor ligands regulate prolactin (PRL) gene expression, we tested the role of HER2/ErbB2 in prolactinoma hormone regulation and adenoma cell proliferation to assess the rationale for targeting this receptor for prolactinoma therapy.
|
21106881 |
2011 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
BIM-23244 reduced PRL secretion only in adenomas expressing sst2, sst5 and DR2. sst5 and DR2 expression correlated directly with BIM23206 inhibitory effects on PRL secretion.
|
16216913 |
2005 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Both are negatively coupled to adenylyl cyclase and inhibit prolactin secretion, but, in addition, the shortest one (D2S) is more efficiently coupled to phospholipase C. Consequently, we also investigated whether expression of a particular D2 receptor isoform was preferentially affected in resistant adenomas.
|
7969790 |
1994 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Bromocriptine (BC) is a well known anti-neoplasic agent in human PRL secreting adenomas although its effect on PRL cells is far from clear.
|
11680511 |
2001 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
By reverse transcriptase polymerase chain reaction (RT-PCR), the coexpression of the two GHS-R isoforms (Ia and Ib) was found in all the GH-, GH-PRL- and PRL-secreting adenomas, and only in two out of three corticotroph, two out of four gonadotroph and one out of five non-secreting tumours.
|
10444306 |
1999 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
By RT-PCR, ER mRNA was found in the nontumorous pituitary and in pituitary adenomas expressing only PRL, in those producing GH and PRL, and in adenomas expressing the gonadotropic hormones.
|
8530610 |
1995 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Common pituitary tumours were prolactin-secreting adenomas (45%), non-functioning pituitary adenomas (NFPAs: 35.6%), growth hormone (GH)-secreting adenomas (10.6%), craniopharyngiomas (7%), and adrenocorticotropic hormone (ACTH)-secreting adenomas (1.8%).
|
29858852 |
2018 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Comparing ISH with immunohistology (IH) we found a correlation between signals and hormone content in 100% of adenomas for GH, in 60% for Prolactin and in 10% for Gonadotropins.
|
1923947 |
1991 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Current guidelines for serum prolactin level cutoffs to distinguish between pathologies are suboptimal because they fail to consider the adenoma volume.
|
31200381 |
2019 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Despite suppression of prolactin levels with cabergoline, the pituitary tumor continued to increase in size and the patient developed clinical symptoms and biochemistry consistent with the diagnosis of acromegaly due to acidophilic stem cell adenoma, an extremely rare subtype of mixed growth hormone/prolactin adenoma, which behaves more aggressively and has a lower surgical cure rate compared to the pure GH-secreting adenoma.
|
31721135 |
2019 |